Koomen, Jeroen V <br/><br/>
Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial.  [electronic resource] 

 -  Diabetes, obesity & metabolism  01 2020 
 - 30-38 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1463-1326 
<br/><br/><label>Standard No.: </label>10.1111/dom.13862  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Cardiovascular Diseases--chemically induced<br/>Clopidogrel--pharmacokinetics<br/>Diabetes Mellitus, Type 2--drug therapy<br/>Double-Blind Method<br/>Drug Interactions<br/>Female<br/>Heart Disease Risk Factors<br/>Humans<br/>Male<br/>Middle Aged<br/>Oxazoles--pharmacokinetics<br/>PPAR alpha--agonists<br/>PPAR gamma--agonists<br/>Risk Factors<br/>Thiophenes--pharmacokinetics